Vinpocetine-AKOS - instructions for use, dose, side effects, contraindications

Excipients: ascorbic acid - 0.5 mg, benzyl alcohol - 10.0 mg, sorbitol (sorbitol) - 100.0 mg, tartaric acid 5.0 mg, sodium disulfite (sodium metabisulphite) -1.0 mg, water for injection - up to 1 ml.

Description:Colorless or greenish-yellow, or yellowish-green color, transparent solution.

Pharmacotherapeutic group:cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons tohypoxia; enhances the trans-transfer of glucose to the brain through the blood-brain barrier; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks calcium-dependent phosphodiesterase; increases the concentration of adenosine monophosphate (AMP), cyclic guanosine monophosphate (cGMP) and adenosine triphosphate (ATP) in the brain. Strengthens the exchange of norepinephrine and serotonin in the brain, has an antioxidant effect. Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by red blood cells; helps to increase the oxygen release of red blood cells. Improves cerebral blood flow; reduces the resistance of cerebral vessels without a significant change in the indices of the systemic circulation. Does not have the effect of "stealing" and increases blood supply, especially in the ischemic regions of the brain. Penetrates through the placental barrier.

Pharmacokinetics:The therapeutic concentration for parenteral administration in plasma is 10-20 ng / ml, the volume of distribution is 5.3 l / kg.The connection with plasma proteins - 66%, clearance - 66.7 l / h, exceeds the plasma volume of the liver (50 l / h), which indicates an extrarenal metabolism. The half-life period is 4-5 hours. It easily penetrates through the histohematological barriers (including the blood-brain barrier), into breast milk (about 0.25% within 1 hour). It is excreted by the kidneys and intestines in the ratio 3: 2.

Indications:

- a decrease in the severity of neurological and mental symptoms in various forms of cerebral circulatory insufficiency (including ischemic stroke, the recovery stage of hemorrhagic stroke, the consequences of a stroke, transient ischemic attack,

- Vascular dementia;

- vertebrobasilar insufficiency;

- Atherosclerosis of cerebral vessels;

- posttraumatic and hypertensive encephalopathy);

- chronic diseases of the choroid and retinal vessels (including occlusion of the central artery or retinal vein);

- Perceptual type hearing loss, Meniere's disease, idiopathic noises in the ears.

Contraindications:

- acute phase of hemorrhagic stroke, severe ischemic heart disease, severe cardiac arrhythmias, hypersensitivity to any of the components of the drug;

- pregnancy (possibly placental bleeding and spontaneous abortion, probably as a result of increased placental blood supply);

- the period of breastfeeding;

- Children under 18 years.

Before using the drug, be sure to consult a doctor.

Carefully:

With hemorrhagic stroke, the introduction is possible only after the subsidence of acute events (usually in 5-7 days).

Pregnancy and lactation:

Use during pregnancy is contraindicated.

During lactation, breastfeeding should be stopped.

Dosing and Administration:

The drug is intended only for intravenous drip infusion, administered slowly (infusion rate should not exceed 80 drops / min). For the preparation of infusion You can use a solution of sodium chloride 0.9% or solutions containing dextrose. The initial daily dose of 20 mg in 500 ml of sodium chloride solution 0.9 % or solutions containing dextrose. With good tolerability for 2-3 days, the dose is raised to a maximum of -1 mg / kg / day.

The average duration of treatment is 10-14 days.

With liver or kidney disease, dose adjustment is not required.

Side effects:From the cardiovascular system: changes on the electrocardiogram (ECG) (depression of the ST segment, prolongation of the Q-T interval); tachycardia, extrasystole, changes in blood pressure (more often decrease).

From the central nervous system: sleep disturbances (insomnia or increased drowsiness), dizziness, headache, general weakness.

From the digestive system: dryness of the oral mucosa, nausea, heartburn.

Other: severe allergic reactions, bronchospasm, increased sweating, skin hyperemia, phlebitis.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose:

Symptoms: increased severity of dose-dependent side effects.

Treatment: symptomatic therapy.

Interaction:

The simultaneous use of vinpocetine and methyldopa sometimes caused some strengthening of the hypotensive effect, so this treatment requires regular monitoring of blood pressure.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution while using central, antiarrhythmic and anticoagulant drugs with the drugs.

Vinpocetine and heparin are chemically incompatible, so they are not allowed to be administered in the same infusion mixture, however, anticoagulants and vinpocetine can be treated concurrently.

Vinpocetine is incompatible with solutions containing amino acids, so they can not be used to dilute it.

Special instructions:

In the case of the initial prolongation of the Q-T interval, as well as simultaneous use with drugs extending the Q-T interval, periodic ECG monitoring is necessary during the treatment with vinpocetine.

The preparation contains sorbitol, therefore, in the presence of diabetes it is necessary to periodically monitor the concentration of glucose in the blood.

Care should be taken when working with mechanisms and performing work that requires rapidity of psychomotor reactions.

Form release / dosage:concentrate for solution for infusion 5 mg / ml

Packaging:

By 2 ml, 5 ml or 10 ml into the ampoules of the light-protective glass.

10 ampoules are placed in a box of cardboard.

By 5 or 10 ampoules are placed in the contour

cell packaging from polyvinylchloride film and foil of aluminum lacquered or without foil.

1 circuit cell package with 10 ampoules or 1, 2 contoured cells with 5 ampoules are placed in a pack of cardboard.

In each pack, the box is attached instructions for use, the ampullar scarifier.

When using ampoules with a kink ring or with a notch and a dot the ampoule scaper is not inserted.

Storage conditions:

In the dark place at a temperature of 15 to 25 ° C.

Keep out of the reach of children.

Shelf life:3 years. Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N001925 / 01-2002

Date of registration:07.08.2008

The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia

Manufacturer: & nbsp

SYNTHESIS, OJSC Russia

COVEX, S.A. Spain

Representation: & nbspSYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products SYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products Russia

Information update date: & nbsp22.09.2015

Illustrated instructions

Instructions

Vinpocetin-AKOS (Vinpocetine-AKOS)